Biogen Inc (BIIB)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $37.46B
Last updated: Nov 17, 2026 at 11:04 AM ET
Biogen Inc (BIIB) P/E Ratio & Valuation History
Biogen (BIIB) trades at 21.4x trailing earnings and 3.6x sales. Its P/E of 21.4x is above its 5-year median of 12.5x. Its forward P/E is 16.4x. The median P/E across 8 similar companies is 14.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 30.5% higher over the next year. Its free cash flow yield is 5.6%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 21.4x |
| Forward P/E | 16.4x |
| Price to sales | 3.6x |
| Price to book | 2.0x |
| EV/EBITDA | 23.0x |
| Price to FCF | 18.0x |
| EV/FCF | 21.0x |
| PEG | 3.5 |
| FCF yield | 5.6% |
Historical Medians
Against its 10-year medians, its P/E is 72.6% above 12.4x, its P/S is 5.9% above 3.4x and its P/B is 37.5% below 3.2x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 21.4x | 12.5x | 12.4x |
| P/S | 3.6x | 3.1x | 3.4x |
| P/B | 2.0x | 2.1x | 3.2x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 7.5x in 2020 to 17.2x in 2023.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $175.99 | 11.5x | 2.6x | 1.4x |
| 2024 | $152.92 | 9.3x | 2.3x | 1.3x |
| 2023 | $258.77 | 17.2x | 3.8x | 2.5x |
| 2022 | $276.92 | 15.7x | 4.0x | 3.0x |
| 2021 | $239.92 | 12.5x | 3.3x | 3.2x |
| 2020 | $244.86 | 7.5x | 2.9x | 3.5x |
| 2019 | $296.73 | 8.8x | 3.9x | 4.0x |
| 2018 | $300.92 | 11.5x | 4.6x | 4.6x |
| 2017 | $318.57 | 14.6x | 5.5x | 5.4x |
| 2016 | $283.58 | 14.0x | 5.4x | 5.1x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BIIB
What is BIIB's forward P/E ratio?
Biogen has a forward P/E ratio of 16.4x.
Is BIIB stock overvalued?
GNG's valuation label for BIIB is Fairly valued. Its P/E of 21.4x compares with a median of 14.5x across 8 similar companies.
What is BIIB's price to sales ratio?
Biogen has a price to sales ratio of 3.6x.
What is Biogen's average P/E ratio over 5 years?
Biogen's median P/E over the last 5 years is 12.5x, from 60 month-end values through Oct 2026.
What is BIIB's PEG ratio?
Biogen has a PEG ratio of 3.5.
BIIB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors